Local bone-building treatment to speed healing of slow-healing fractures
Effective local delivery of bone anabolic agent to accelerate the healing of delayed fracture union
A temperature-sensitive gel that delivers a bone-building drug directly to slow-healing fractures to help people whose breaks are delayed or at risk of not healing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11248854 on NIH RePORTER |
What this research studies
Researchers are developing a temperature-sensitive gel that carries a bone-building medicine (Tanshinone IIA) and turns into a gel at body temperature so it stays at the injury site. The gel is built from a water-soluble polymer (HPMA) that helps release the drug locally over time. The project uses laboratory and animal models of delayed fracture healing, including damage caused by steroid (glucocorticoid) exposure, to test whether local delivery speeds repair. If successful, this approach could offer a non-surgical treatment option for fractures that are slow to heal.
Who could benefit from this research
Good fit: People with fractures that are not healing on schedule (delayed union) or who are at high risk for non-union, especially those with steroid use, diabetes, smoking, or heavy alcohol use.
Not a fit: People whose fractures are healing normally, who need immediate surgical fixation, or who have allergies or sensitivities to the treatment components are unlikely to benefit.
Why it matters
Potential benefit: Could speed bone repair, reduce chronic pain and disability, and lower the need for surgery or bone grafts.
How similar studies have performed: Some local bone-growth therapies (for example BMP-based products) have worked in certain situations, but this specific Tanshinone IIA hydrogel prodrug approach is novel and has mainly been tested in lab and animal studies so far.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Wang, Dong — University of Nebraska Medical Center
- Study coordinator: Wang, Dong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.